Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

85.90USD
2:16pm EST
Change (% chg)

$-2.19 (-2.49%)
Prev Close
$88.09
Open
$88.50
Day's High
$88.78
Day's Low
$85.38
Volume
613,994
Avg. Vol
1,545,285
52-wk High
$125.84
52-wk Low
$77.50

Select another date:
Photo

Roche-AbbVie cancer drug gets accelerated FDA approval

Roche Holding AG said on Wednesday its cancer drug, Venclexta, received accelerated approval from the U.S. Food and Drug Administration as part of a combination treatment for newly diagnosed patients with a form of leukemia.

CORRECTED-UPDATE 1-Roche-AbbVie cancer drug gets accelerated FDA approval

Nov 21 Roche Holding AG said on Wednesday its cancer drug, Venclexta, received accelerated approval from the U.S. Food and Drug Administration as part of a combination treatment for newly diagnosed patients with a form of leukemia.

Roche-AbbVie cancer drug gets accelerated FDA approval

Nov 21 Roche Holding AG said on Wednesday its cancer drug, Venclexta, received accelerated approval from the U.S. Food and Drug Administration as part of a combination treatment for newly diagnosed patients with a form of leukemia.

AbbVie sees hit to Humira sales from European competition

U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.

UPDATE 3-AbbVie sees hit to Humira sales from European competition

Nov 2 U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.

CORRECTED-UPDATE 2-AbbVie sees hit to Humira sales from European competition

Nov 2 U.S. drugmaker AbbVie Inc on Friday lowered its overseas sales forecast for its top-selling medicine, Humira, as it agreed to larger-than-expected price cuts due to new European competition.

Humira biosimilars available at up to 80 percent discount in Europe: AbbVie

AbbVie Inc said on Friday rival biosimilar versions of its best-selling drug Humira were available in Europe at discounts ranging from 10 percent to 80 percent.

Humira biosimilars available at up to 80 pct discount in Europe-AbbVie

Nov 2 AbbVie Inc said on Friday rival biosimilar versions of its best-selling drug Humira were available in Europe at discounts ranging from 10 percent to 80 percent.

AbbVie expects double-digit earnings growth in 2019

AbbVie Inc said on Friday it was confident that its earnings would grow in the double digits in 2019, in spite of the launch of biosimilar versions of its best-selling rheumatoid arthritis drug Humira in the European Union.

AbbVie expects double-digit earnings growth in 2019

Nov 2 AbbVie Inc said on Friday it was confident that its earnings would grow in the double digits in 2019, in spite of the launch of biosimilar versions of its best-selling rheumatoid arthritis drug Humira in the European Union.

Select another date: